Rate Video

iwMyeloma 2015 | Novel HDAC6 inhibitor, ricolinostat, for the treatment of multiple myeloma

Noopur Raje • 11 Apr 2015

Multiple Myeloma

At the Myeloma 2015 meeting, Dr Noopur Raje (Massachusetts General Hospital, Boston, MA) discusses the clinical development of the selective histone deacetylase 6 (HDAC6) inhibitor, ricolinostat, for the treatment of multiple myeloma. Clinical results to date suggest that ricolinostat is likely to operate synergistically with other agents.

Myeloma 2016: Panel discussion on in vivo drug screening

Caroline Heckman et al.

Where does MRD belong as a tool in myeloma?

Noopur Raje • 29 Nov 2021

CAR-T and cellular therapy at ASH 2020

Noopur Raje • 23 Nov 2020

MAIA & TOURMALINE-MM3: updates in newly diagnosed multiple myeloma

Related Videos

Updates from the LocoMMotion study

Hermann Einsele • 11 Jun 2022

Safety and efficacy of teclistamab in patients with triple-class exposed R/R myeloma

Hermann Einsele • 11 Jun 2022

Safety and efficacy of REGN5458 in patients with relapsed/refractory (R/R) multiple myeloma

Joshua Richter • 11 Jun 2022

Updated results from CARTITUDE-1

Yi Lin • 11 Jun 2022